To understand differences in neural activity between FXS and non-FXS individuals when responding to different frequencies, Thorpe said, researchers played an auditory “chirp,” or sound stimulus, and ...

Despite modern high-throughput sequencing, the genetic cause of most rare movement disorders remains unclear. A research team in Bochum and Tübingen has now solved one piece of the puzzle: The ...

Stanford Medicine pediatric hematologist Agnieszka Czechowicz, MD, Ph.D., has devoted her research career to improving ...

Explore neuroscience breakthroughs reshaping treatments for Alzheimer’s, Parkinson’s, PTSD, and other brain disorders.

UAB is participating in a Phase I/II trial of AMT 191, a one time gene therapy designed to enable patients with classic Fabry disease to produce their own missing enzyme, potentially reducing the need ...

March 16 (Reuters) - BioMarin Pharmaceutical will discontinue mid-stage trials of its bone disorder treatment after reports of several cases of patients' hip joint slipping out of place, the drugmaker ...

Jeremy Michael, a Muskingum University student-athlete, died from hypertrophic cardiomyopathy, a genetic heart disease.

Despite modern high-throughput sequencing, the genetic cause of most rare movement disorders remains unclear. A research team in Bochum and Tübingen has now solved one piece of the puzzle: The ...

Abeona Therapeutics (ABEO) stock gets a "Buy" rating, driven by ZEVASKYN's commercial launch for RDEB and strong early demand signals. Read the full analysis here.

Shane DiGiovanna was born with epidermolysis bullosa, or EB, a condition he said is described as "the worst disease you’ve never heard of." ...

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced the first patients were enrolled in Esprit, a global Phase 2 clinical ...

Pets encounter a variety of everyday risks, from outdoor threats like animals or parasites to physical dangers like vehicles ...